person · Reporting owner

Greenleaf Peter

Disclosed activity across 9 companies

Tapewire entity: 31647
SEC CIK: 0001363683

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463	Director · Chief Executive Officer	February 27, 2026	March 03, 2026
Avalo Therapeutics, Inc.CERC · Entity 4936	Director	August 07, 2019	October 03, 2019
KIORA PHARMACEUTICALS INCEYEG · Entity 7940	Director	February 01, 2019	February 05, 2019
Pelthos Therapeutics Inc.PTHS · Entity 6798	Director	October 02, 2026	October 06, 2026
SYNLOGIC, INC.MIRN · Entity 7801	Director	June 29, 2016	September 06, 2016
Savara IncMSTX · Entity 4900	Director	January 20, 2017	January 23, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aurinia Pharmaceuticals Inc.

Report date February 27, 2026 · Filed March 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,840,379	Ending reported balance After 2026-03-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-02-27 · Grant · Acquired 196,403 · Balance 1,941,269 F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Row 2 · 2026-03-02 · Tax withholding · Disposed 100,890 · Balance 1,840,379 F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.97 · Expires 2036-02-27	Direct	328,424	Reported balance After 2026-02-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-27 · Grant · Acquired 328,424 · Balance 328,424 F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.

F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Avalo Therapeutics, Inc.

Report date August 07, 2019 · Filed October 03, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2029-08-07	Direct	25,000	Reported balance After 2019-08-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-08-07 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2027-05-12	Direct	16,714	Reported balance Holding disclosure · report date 2019-08-07 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 16,714 F3: The stock option will vest in three substantially equal annual installments on May 11, 2018, 2019 and 2020, subject to the Reporting Person's continued service on each such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2027-06-30	Direct	8,357	Reported balance Holding disclosure · report date 2019-08-07 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 8,357 F2: The stock option is fully vested.
Common StockSEC Table I · non-derivative	Direct	112,500	Reported balance Holding disclosure · report date 2019-08-07 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 112,500
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2028-03-27	Direct	135,417	Reported balance Holding disclosure · report date 2019-08-07 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 135,417 F2: The stock option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date.

F2: The stock option is fully vested.

F3: The stock option will vest in three substantially equal annual installments on May 11, 2018, 2019 and 2020, subject to the Reporting Person's continued service on each such vesting date.

KIORA PHARMACEUTICALS INC

Report date February 01, 2019 · Filed February 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2029-02-01	Direct	50,000	Reported balance After 2019-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-02-01 · Grant · Acquired 50,000 · Balance 50,000 F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020.

Pelthos Therapeutics Inc.

Report date October 02, 2026 · Filed October 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,087	Reported balance After 2026-10-02 transaction · row 1 1 source row Row 1 · 2026-10-02 · Sale · Disposed 797 · Balance 23,087 F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

SYNLOGIC, INC.

Report date June 29, 2016 · Filed September 06, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2026-06-29	Direct	10,000	Reported balance After 2016-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-06-29 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Savara Inc

Report date January 20, 2017 · Filed January 23, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	45,535	Reported balance After 2017-01-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-01-20 · Grant · Acquired 45,535 · Balance 45,535 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017).

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017).

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ANTARES PHARMA, INC.

Report date May 24, 2022 · Filed May 26, 2022

Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-05-24 · Disposition to issuer · Disposed 30,220 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-24 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2022-05-24 · Disposition to issuer · Disposed 49,425 · Balance 0 F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11	Direct	Reported balance After 2022-05-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-24 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92	Direct	Reported balance After 2022-05-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-24 · Disposition to issuer · Disposed 46,729 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.73	Direct	Reported balance After 2022-05-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-24 · Disposition to issuer · Disposed 58,246 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42	Direct	Reported balance After 2022-05-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-24 · Disposition to issuer · Disposed 48,542 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

BIODELIVERY SCIENCES INTERNATIONAL INC

Report date March 22, 2022 · Filed March 22, 2022

Section 16 reporting ended · disclosed 2022-03-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-03-22 transaction · row 1 1 source row Row 1 · 2022-03-22 · Other · Disposed 105,034 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2022-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-03-22 · Disposition to issuer · Disposed 27,746 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93	Direct	Reported balance After 2022-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-03-22 · Disposition to issuer · Disposed 64,164 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66	Direct	Reported balance After 2022-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-03-22 · Disposition to issuer · Disposed 114,347 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Sucampo Pharmaceuticals, Inc.

Report date February 13, 2018 · Filed February 13, 2018

Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, Class ASEC Table I · non-derivative	Direct	Reported balance After 2018-02-13 transaction · row 1 1 source row Row 1 · 2018-02-13 · Disposition to issuer · Disposed 129,729 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of both common stock and restricted stock units that were accelerated as a result of the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.49 · Expires 2024-03-03	Direct	Reported balance After 2018-02-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-02-13 · Disposition to issuer · Disposed 600,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2024-07-31	Direct	Reported balance After 2018-02-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-02-13 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2025-03-04	Direct	Reported balance After 2018-02-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-02-13 · Disposition to issuer · Disposed 210,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2026-03-02	Direct	Reported balance After 2018-02-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-02-13 · Disposition to issuer · Disposed 420,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2027-03-02	Direct	Reported balance After 2018-02-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-02-13 · Disposition to issuer · Disposed 237,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of both common stock and restricted stock units that were accelerated as a result of the Merger Agreement.

F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 02, 2026 Filed Oct 6, 2026 21:54 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	SaleCommon Stock	797	$21.17	$16,872.49	Disclosure SEC source: 0001919246-26-000131 · wk-form4_1791323650.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,087 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. Read SEC document
July 02, 2026 Filed Jul 7, 2026 21:03 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	SaleCommon Stock	85	$27.27	$2,318.23	Disclosure SEC source: 0001919246-26-000100 · wk-form4_1783458198.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,884 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
July 02, 2026 Filed Jul 7, 2026 21:03 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	SaleCommon Stock	712	$26.00	$18,508.72	Disclosure SEC source: 0001919246-26-000100 · wk-form4_1783458198.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,969 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.58 to $26.53. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
April 02, 2026 Filed Apr 6, 2026 21:01 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	SaleCommon Stock	377	$21.36	$8,053.25	Disclosure SEC source: 0001919246-26-000052 · wk-form4_1775509257.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,681 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
April 02, 2026 Filed Apr 6, 2026 21:01 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	SaleCommon Stock	420	$20.52	$8,616.34	Disclosure SEC source: 0001919246-26-000052 · wk-form4_1775509257.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,058 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:13 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	Tax withholdingCommon Stock	100,890	$14.21	$1,433,646.90	Disclosure SEC source: 0001600620-26-000021 · wk-form4_1772572423.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,840,379 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:13 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantEmployee Stock Option (right to buy) · Derivative	328,424	$0.00 Strike: $13.97	$0.00	Disclosure SEC source: 0001600620-26-000021 · wk-form4_1772572423.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,424 Underlying: Common Stock · 328,424 shares Expires 2036-02-27 F3 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:13 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Stock	196,403	$0.00	$0.00	Disclosure SEC source: 0001600620-26-000021 · wk-form4_1772572423.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,941,269 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Read SEC document
February 20, 2026 Filed Feb 23, 2026 21:07 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	Tax withholdingCommon Stock	100,171	$14.40	$1,442,462.40	Disclosure SEC source: 0001363683-26-000002 · wk-form4_1771880820.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,744,866 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:10 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	Tax withholdingCommon Stock	113,169	$15.95	$1,805,045.55	Disclosure SEC source: 0001600620-26-000002 · wk-form4_1767647395.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,845,037 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards. F3 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,257 common shares were acquired on May 30, 2025 and 1,620 common shares were acquired on November 28, 2025. Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:10 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Stock	165,384	$0.00	$0.00	Disclosure SEC source: 0001600620-26-000002 · wk-form4_1767647395.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,954,329 F1 · shares: Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026. Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:46 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantStock Option · Derivative	77,640	Not disclosed Strike: $13.50	Not disclosed	Disclosure SEC source: 0001753926-25-001108 · ownership.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,640 Underlying: Common Stock · 77,640 shares Expires 2035-07-02 F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:46 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantRestricted Stock Units · Derivative	25,478	Not disclosed Strike: $13.50	Not disclosed	Disclosure SEC source: 0001753926-25-001108 · ownership.xml · derivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,478 Underlying: Common Stock · 25,478 shares Expires 2035-07-02 F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document
July 02, 2025 Filed Apr 1, 2026 21:43 UTC Amendment	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantCommon Stock	25,478	$0.00	$0.00	Disclosure SEC source: 0001919246-26-000043 · wk-form4a_1775079819.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,478 F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary. Read SEC document
March 04, 2025 Filed Mar 5, 2025 02:02 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	SaleCommon Stock	164,947	$7.92	$1,306,380.24	Disclosure SEC source: 0001600620-25-000024 · wk-form4_1741140121.xml · nonDerivative · entry 4 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,788,945 F6 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants. F7 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 03, 2025 Filed Mar 5, 2025 02:02 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	SaleCommon Stock	195,593	$8.00	$1,564,744.00	Disclosure SEC source: 0001600620-25-000024 · wk-form4_1741140121.xml · nonDerivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,953,892 F4 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award. F5 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 03, 2025 Filed Mar 5, 2025 02:02 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Stock	333,705	$0.00	$0.00	Disclosure SEC source: 0001600620-25-000024 · wk-form4_1741140121.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,149,485 F3 · shares: Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025. Read SEC document
February 28, 2025 Filed Mar 5, 2025 02:02 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantEmployee Stock Option (right to buy) · Derivative	443,973	$0.00 Strike: $7.55	$0.00	Disclosure SEC source: 0001600620-25-000024 · wk-form4_1741140121.xml · derivative · entry 5 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,973 Underlying: Common Stock · 443,973 shares Expires 2035-02-28 F8 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document
February 28, 2025 Filed Mar 5, 2025 02:02 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Stock	290,728	$0.00	$0.00	Disclosure SEC source: 0001600620-25-000024 · wk-form4_1741140121.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,815,780 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. F2 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024. Read SEC document
March 06, 2024 Filed Mar 7, 2024 21:46 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	SaleCommon Stock	126,981	$5.60	$711,093.60	Disclosure SEC source: 0001600620-24-000038 · wk-form4_1709847968.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,522,114 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2022 and March 2, 2023 grants. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 20, 2024 Filed Feb 22, 2024 21:25 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Stock	661,538	$0.00	$0.00	Disclosure SEC source: 0001600620-24-000017 · wk-form4_1708637079.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,649,095 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,386 shares of common stock were acquired on May 31, 2023 and 2,500 shares of common stock were acquired on November 30, 2023. Read SEC document
March 02, 2023 Filed Mar 6, 2023 21:27 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	SaleCommon Stock	32,750	$8.94	$292,785.00	Disclosure SEC source: 0001628280-23-006526 · wf-form4_167813805672591.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982,968 F5 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document
March 02, 2023 Filed Mar 6, 2023 21:27 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Stock	667,407	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-006526 · wf-form4_167813805672591.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,718 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,221 shares of common stock were acquired on May 31, 2022 and 1,883 shares of common stock were acquired on November 30, 2022. F4 · balance_after: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 667,407 newly awarded RSUs, 312,240 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 32,967 shares of common stock. On March 2, 2023, 104,080 of Prior RSUs vested and 208,160 of Prior RSUs remained unvested. Read SEC document
March 02, 2023 Filed Feb 22, 2024 21:15 UTC Amendment	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	SaleCommon Stock	33,047	$8.78	$290,152.66	Disclosure SEC source: 0001600620-24-000013 · wk-form4a_1708636492.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 982,671 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document
May 24, 2022 Filed May 26, 2022 17:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	48,542	Not disclosed Strike: $4.42	Not disclosed	Disclosure SEC source: 0000899243-22-019780 · doc4.xml · derivative · entry 6 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,542 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	58,246	Not disclosed Strike: $2.73	Not disclosed	Disclosure SEC source: 0000899243-22-019780 · doc4.xml · derivative · entry 5 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,246 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	46,729	Not disclosed Strike: $2.92	Not disclosed	Disclosure SEC source: 0000899243-22-019780 · doc4.xml · derivative · entry 4 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,729 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	20,000	Not disclosed Strike: $3.11	Not disclosed	Disclosure SEC source: 0000899243-22-019780 · doc4.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerCommon Stock	49,425	$5.60	$276,780.00	Disclosure SEC source: 0000899243-22-019780 · doc4.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document
May 24, 2022 Filed May 26, 2022 17:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerCommon Stock	30,220	$5.60	$169,232.00	Disclosure SEC source: 0000899243-22-019780 · doc4.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:12 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Disposition to issuerStock Options (right to buy) · Derivative	114,347	$0.00 Strike: $3.66	$0.00	Disclosure SEC source: 0001103021-22-000067 · wf-form4_164798354676336.xml · derivative · entry 4 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,347 shares Expires not disclosed F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:12 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Disposition to issuerStock Options (right to buy) · Derivative	64,164	$0.00 Strike: $2.93	$0.00	Disclosure SEC source: 0001103021-22-000067 · wf-form4_164798354676336.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,164 shares Expires not disclosed F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:12 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Disposition to issuerRestricted Stock Units · Derivative	27,746	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001103021-22-000067 · wf-form4_164798354676336.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,746 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3 · price: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. F3 · derivative.exercise_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. F3 · derivative.expiration_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:12 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	OtherCommon Stock	105,034	$0.00	$0.00	Disclosure SEC source: 0001103021-22-000067 · wf-form4_164798354676336.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. Read SEC document
March 02, 2022 Filed Mar 4, 2022 21:11 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantStock Option (right to buy) · Derivative	534,188	$0.00 Strike: $12.01	$0.00	Disclosure SEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · derivative · entry 4 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,188 Underlying: Common Stock · 534,188 shares Expires 2032-03-02 F5 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document
March 02, 2022 Filed Mar 4, 2022 21:11 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantRestricted Stock Unit · Derivative	312,240	$0.00	$0.00	Disclosure SEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,240 Underlying: Common Shares · 312,240 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document
March 02, 2022 Filed Mar 4, 2022 21:11 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	SaleCommon Stock	9,068	$12.01	$108,906.68	Disclosure SEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,967 F3 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document
March 02, 2022 Filed Mar 4, 2022 21:11 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Stock	28,300	$0.00	$0.00	Disclosure SEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,035 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 282 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document
January 27, 2022 Filed Jan 31, 2022 18:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionRestricted Stock Units · Derivative	10,246	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001103021-22-000021 · wf-form4_164367011540849.xml · derivative · entry 4 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,246 Underlying: Common Stock · 10,246 shares Expires 2023-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023. Read SEC document
January 27, 2022 Filed Jan 31, 2022 18:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantRestricted Stock Units · Derivative	20,492	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001103021-22-000021 · wf-form4_164367011540849.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,492 Underlying: Common Stock · 20,492 shares Expires 2023-01-27 F1 · kind: The restricted stock units ("RSUs") were issued to the Reporting Person as compensation for service on the Company's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan ("the Plan"). The RSUs vest in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023. F1 · derivative.exercise_date: The restricted stock units ("RSUs") were issued to the Reporting Person as compensation for service on the Company's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan ("the Plan"). The RSUs vest in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023. Read SEC document
January 27, 2022 Filed Jan 31, 2022 18:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantStock Options (right to buy) · Derivative	114,347	$3.66 Strike: $3.66	$418,510.02	Disclosure SEC source: 0001103021-22-000021 · wf-form4_164367011540849.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,347 Underlying: Common Stock · 114,347 shares Expires 2032-01-26 F2 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022. F3 · kind: The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023. F3 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023. Read SEC document
January 27, 2022 Filed Jan 31, 2022 18:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	10,246	$0.00	$0.00	Disclosure SEC source: 0001103021-22-000021 · wf-form4_164367011540849.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units ("RSUs") were issued to the Reporting Person as compensation for service on the Company's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan ("the Plan"). The RSUs vest in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023. Read SEC document
August 06, 2021 Filed Aug 10, 2021 18:17 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001103021-21-000070 · wf-form4_162863384146877.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 35,000 shares Expires 2022-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
August 06, 2021 Filed Aug 10, 2021 18:17 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0001103021-21-000070 · wf-form4_162863384146877.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 10, 2021 Filed Jun 14, 2021 18:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantStock Option (right to buy) · Derivative	48,542	$0.00 Strike: $4.42	$0.00	Disclosure SEC source: 0001209191-21-040329 · doc4.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,542 Underlying: Common Stock · 48,542 shares Expires 2031-06-10 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable one year from the grant date. Read SEC document
June 10, 2021 Filed Jun 14, 2021 18:22 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantCommon Stock	25,452	$4.42	$112,497.84	Disclosure SEC source: 0001209191-21-040329 · doc4.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,645 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date. Read SEC document
May 11, 2021 Filed May 12, 2021 20:32 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	PurchaseCommon Stock	2,992	$11.11	$33,241.12	Disclosure SEC source: 0001628280-21-010022 · wf-form4_162085152431857.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,453 F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.91 to $11.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
May 11, 2021 Filed May 12, 2021 20:32 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	PurchaseCommon Stock	2,133	$10.15	$21,649.95	Disclosure SEC source: 0001628280-21-010022 · wf-form4_162085152431857.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,461 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $9.74 to $10.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
August 07, 2020 Filed Aug 11, 2020 17:03 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001103021-20-000132 · wf-form4_159717982037683.xml · derivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 35,000 shares Expires 2022-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (ii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document
August 07, 2020 Filed Aug 11, 2020 17:03 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0001103021-20-000132 · wf-form4_159717982037683.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (ii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.